Alteration of pallidal cholinergic activity in MPTP-treated monkeys: effect of dihydro-alpha-ergocryptine (DEK)

Neurosci Lett. 1994 Feb 28;168(1-2):213-6. doi: 10.1016/0304-3940(94)90453-7.

Abstract

Monkeys, intravenously administered with MPTP at the dose of 0.3 mg/kg for 5 consecutive days, develop a severe Parkinson-like syndrome. Cholinergic enzyme activities are increased in the internal segment of the globus pallidus (GPi) and into a lesser extent in the external globus pallidus (GPe). Cholinergic activities are not significantly affected in the caudate and putamen nor in the frontal, parietotemporal, occipital cortices and in the cerebellum. The treatment of the animals twice daily for 2 weeks with dihydro-alpha-ergocryptine (DEK) starting 5 days before the first MPTP administration counteracts the neurotoxin-induced alteration in the internal pallidum and ameliorates some motor related parkinsonian symptoms.

MeSH terms

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / antagonists & inhibitors
  • Acetylcholinesterase / metabolism*
  • Animals
  • Brain / drug effects
  • Brain / enzymology
  • Brain / physiopathology*
  • Choline O-Acetyltransferase / metabolism*
  • Dihydroergotoxine / pharmacology*
  • Globus Pallidus / drug effects
  • Globus Pallidus / enzymology
  • Globus Pallidus / physiopathology*
  • MPTP Poisoning*
  • Macaca fascicularis
  • Male
  • Motor Activity / drug effects*
  • Organ Specificity
  • Parkinson Disease, Secondary / chemically induced
  • Parkinson Disease, Secondary / enzymology
  • Parkinson Disease, Secondary / physiopathology*
  • Posture
  • Pyruvate Dehydrogenase Complex / metabolism*
  • Time Factors
  • Tremor

Substances

  • Pyruvate Dehydrogenase Complex
  • Dihydroergotoxine
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Choline O-Acetyltransferase
  • Acetylcholinesterase